Developer docs
API playgroundTry for free, no card

Search company profiles

TeVido BioDevices

Full company profile

uuid0002adt

Namestring
TeVido BioDevices
Websiteurl
tevidobiodevices.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

TeVido BioDevices is an early-stage regenerative medicine company founded in 2011 and headquartered in Austin, Texas. The company develops autologous skin cell transplantation therapies, with its stated mission being to make "life-changing skin cell transplants available to those who need them." The underlying technology centers on cell-based skin grafting approaches, likely incorporating 3D bioprinting techniques to fabricate living tissue constructs from a patient's own cells. Implicit target indications include burn treatment, post-mastectomy reconstruction, chronic wound care, and other dermatological applications requiring living tissue replacement. The company is led by Founder and CEO Laura Bosworth and CTO Lindsay Sulzer, with a micro-team of 1-10 employees consistent with pre-clinical or early translational development stage.

TeVido has raised approximately $3.75 million in cumulative funding across grants, angel rounds, and accelerator participation over an eight-year span (2012-2020). Capital sources include two National Science Foundation SBIR awards ($150,000 in 2012 and $951,999 in 2014), angel rounds from Central Texas Angel Network, Life Science Angels, and Texas HALO Fund (~$1.2 million in January 2019), an additional ~$1.42 million raise in January 2019, a Texas A&M Innovation award ($25,000 in 2015), and participation in MassChallenge (2020) and Texas Venture Labs (2012). The funding mix — heavily weighted toward non-dilutive federal grants supplemented by regional angel capital — is characteristic of academic-spinout and translational-stage biotech companies.

No commercial revenue model, pricing structure, customer segments, or distribution channels have been disclosed in available data, consistent with a pre-commercial stage. Critically, the company's website domain (tevidobiodevices.com) currently displays unrelated content rather than company information, which represents either a domain lapse, an operational disruption, or a data-source anomaly. This operational signal materially affects any assessment of current activity and should be resolved before commercial or investment conclusions are drawn.

Short descriptiontext

TeVido BioDevices is an Austin, Texas-based regenerative medicine company developing autologous skin cell transplant therapies for patients requiring advanced tissue repair, including burn and reconstruction applications. Founded in 2011, it operates at pre-clinical stage with a 1-10 person team.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
skin cell transplants, regenerative medicine, 3D bioprinting, tissue engineering, wound care biologics
Industry3 codes
1Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
CodeHLAHALAEPrimaryYes
2Cartilage, Bone & Musculoskeletal Regeneration
CodeHLAAAGAHPrimaryNo
3Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
CodeHLAAAGABPrimaryNo
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine / Bioengineered Skin Tissue
Social media profiles2 records
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

TeVido BioDevices makes life-changing skin cell transplants available to patients, using bioprinting technology to fabricate skin tissue for therapeutic use. The company focuses on bioengineered skin constructs intended for chronic wounds, burns, and reconstructive indications, serving clinicians and patients needing advanced skin-substitute solutions.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Skin Cell Transplants
CategoryBioengineered Skin Tissue / Regenerative Medicine
Description

Life-changing bioengineered skin cell transplants intended for patients needing advanced skin substitutes for chronic wounds, burns, and reconstructive indications.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TeVido BioDevices

Regenerative Medicine / Bioengineered Skin Tissuetevidobiodevices.com

TeVido BioDevices is an Austin, Texas-based regenerative medicine company developing autologous skin cell transplant therapies for patients requiring advanced tissue repair, including burn and reconstruction applications. Founded in 2011, it operates at pre-clinical stage with a 1-10 person team.

What TeVido BioDevices does

TeVido BioDevices is an early-stage regenerative medicine company founded in 2011 and headquartered in Austin, Texas. The company develops autologous skin cell transplantation therapies, with its stated mission being to make "life-changing skin cell transplants available to those who need them." The underlying technology centers on cell-based skin grafting approaches, likely incorporating 3D bioprinting techniques to fabricate living tissue constructs from a patient's own cells. Implicit target indications include burn treatment, post-mastectomy reconstruction, chronic wound care, and other dermatological applications requiring living tissue replacement. The company is led by Founder and CEO Laura Bosworth and CTO Lindsay Sulzer, with a micro-team of 1-10 employees consistent with pre-clinical or early translational development stage.

TeVido has raised approximately $3.75 million in cumulative funding across grants, angel rounds, and accelerator participation over an eight-year span (2012-2020). Capital sources include two National Science Foundation SBIR awards ($150,000 in 2012 and $951,999 in 2014), angel rounds from Central Texas Angel Network, Life Science Angels, and Texas HALO Fund (~$1.2 million in January 2019), an additional ~$1.42 million raise in January 2019, a Texas A&M Innovation award ($25,000 in 2015), and participation in MassChallenge (2020) and Texas Venture Labs (2012). The funding mix — heavily weighted toward non-dilutive federal grants supplemented by regional angel capital — is characteristic of academic-spinout and translational-stage biotech companies.

No commercial revenue model, pricing structure, customer segments, or distribution channels have been disclosed in available data, consistent with a pre-commercial stage. Critically, the company's website domain (tevidobiodevices.com) currently displays unrelated content rather than company information, which represents either a domain lapse, an operational disruption, or a data-source anomaly. This operational signal materially affects any assessment of current activity and should be resolved before commercial or investment conclusions are drawn.

TeVido BioDevices firmographics

Firmographics
Name
TeVido BioDevices
Website
https://tevidobiodevices.com
Company type
Private
Founded year
2011
Headcount range
1–10 employees
Short description
TeVido BioDevices is an Austin, Texas-based regenerative medicine company developing autologous skin cell transplant therapies for patients requiring advanced tissue repair, including burn and reconstruction applications. Founded in 2011, it operates at pre-clinical stage with a 1-10 person team.
Ownership category
akta.pro rank

TeVido BioDevices industry classification

Industry
Product category
Regenerative Medicine / Bioengineered Skin Tissue
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
akta.pro secondary industries
Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

Keywords

  • Skin cell transplants
  • Regenerative medicine
  • 3D bioprinting
  • Tissue engineering
  • Wound care biologics

Where TeVido BioDevices is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Markets served

TeVido BioDevices business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

TeVido BioDevices product offering

Product offering

Core offering

TeVido BioDevices makes life-changing skin cell transplants available to patients, using bioprinting technology to fabricate skin tissue for therapeutic use. The company focuses on bioengineered skin constructs intended for chronic wounds, burns, and reconstructive indications, serving clinicians and patients needing advanced skin-substitute solutions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Skin Cell Transplants Life-changing bioengineered skin cell transplants intended for patients needing advanced skin substitutes for chronic wounds, burns, and reconstructive indications.

Companies that use TeVido BioDevices

Customer profile

Ideal customer profiles1 record

TeVido BioDevices technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

TeVido BioDevices partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights3 records

TeVido BioDevices competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

TeVido BioDevices social profiles

Digital presence

TeVido BioDevices financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TeVido BioDevices leadership team

Management profile

Number of profiles

Profiles2 records

TeVido BioDevices funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TeVido BioDevices M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TeVido BioDevices

What does TeVido BioDevices do?

TeVido BioDevices makes life-changing skin cell transplants available to patients, using bioprinting technology to fabricate skin tissue for therapeutic use. The company focuses on bioengineered skin constructs intended for chronic wounds, burns, and reconstructive indications, serving clinicians and patients needing advanced skin-substitute solutions.

Is TeVido BioDevices a public or private company?

TeVido BioDevices is a private company. It is classified as venture growth investor backed.

When was TeVido BioDevices founded?

TeVido BioDevices was founded in 2011. It employs 1 to 10 people.

Where is TeVido BioDevices based?

TeVido BioDevices is headquartered in Austin, United States, in the North America region.

Does TeVido BioDevices have an API?

No public API is recorded for TeVido BioDevices.

What industry is TeVido BioDevices in?

TeVido BioDevices's product category is Regenerative Medicine / Bioengineered Skin Tissue. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Medical Futurist3D Bioprinting: These Are The Top 15 Bioprinting CompaniesThe Medical Futurist published a 2024 update of a 2018 list of 15 bioprinting companies, tracking their developments over six years. Several firms such as TeVido, Digilab, n3D and Rokit closed, while Cellink became the first EIC-funded unicorn, Aspect raised $72.75 million, and Organovo shifted to drug development.TechCrunchTeVido BioDevices 3D-Prints Skin And Fat Grafts For Breast Cancer SurvivorsTeVido BioDevices, a startup led by former Dell executive Laura Bosworth, is developing 3D printing technology to create skin and fat grafts from a patient's own cells for breast cancer survivors who have undergone lumpectomies or mastectomies. The company, founded in 2011 with Dr. Thomas Boland (a pioneer in bioprinting), has completed initial lab tests on a $150,000 National Science Foundation grant and is now seeking funding for the next testing phase, with products still approximately five years from market pending FDA approval. The company estimates a market opportunity of at least $6 billion for its planned products, which include nipple reconstruction and fat grafts for various medical and cosmetic applications.TechCrunchMexico’s Resources Fuel The Texas Startup EconomyThis column-style article examines how Texas startups and tech companies benefit from their proximity to Mexico, the state's number one trading partner, through manufacturing capabilities, skilled talent, and shorter supply chains compared to China. Specific examples include SpaceX planning a rocket launch site in Brownsville near Mexican manufacturing facilities, Johnson & Johnson's production of pacemakers and heart stents in the El Paso-Ciudad Juárez region, and iTexico CEO Anurag Kumar winning Mexico's 2014 National Entrepreneurship Award for leveraging Mexican IT talent. The article notes that while many companies find Mexico advantageous, some startups like TeVido Biodevices have struggled to find suitable biotech infrastructure and are relocating to Austin.